Age affects drug survival rates of interleukin (IL)-17 and IL-23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi-country, cohort study.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
11 Jun 2024
11 Jun 2024
Historique:
received:
02
02
2024
accepted:
18
04
2024
medline:
11
6
2024
pubmed:
11
6
2024
entrez:
11
6
2024
Statut:
aheadofprint
Résumé
Scarce data related to the drug survival of biologic agents in psoriasis patients aged ≥65 years is available. To evaluate the drug survival of interleukin (IL)-23 or the IL-17 inhibitors approved for the treatment of moderate-to-severe psoriasis in elderly patients (aged ≥65 years), compared with younger adult patients (aged <65 years), and to identify clinical predictors that can influence the drug survival. This retrospective multicentric cohort study included adult patients with moderate-to-severe psoriasis, dissecting two-patient subcohorts based on age: elderly versus younger adults. Kaplan-Meier estimator and proportional hazard Cox regression models were used for drug survival analysis. We included 4178 patients and 4866 treatment courses; 934 were elderly (1072 treatment courses), and 3244 were younger patients (3794 treatment courses). Drug survival, considering all causes of interruption, was higher in patients aged <65 years than in elderly patients overall (log-rank p < 0.006). This difference was significant for treatment courses involving IL-23 inhibitors (p < 0.001) but not for those with IL-17 inhibitors (p = 0.2). According to both uni- and multi-variable models, elder age was associated with an increased risk of treatment discontinuation (univariable analysis: HR: 1.229, 95% CI 1.062-1.422; p < 0.006; multivariable analysis: HR: 1.199, 95% CI 1.010-1.422; p = 0.0377). Anti-IL-23 agents were associated with a reduced likelihood of treatment discontinuation after adjusting for other variables (HR: 0.520, 95% CI 0.368-0.735; p < 0.001). Being previously treated with IL-17 inhibitors increased the probability of discontinuation. Elderly patients with psoriasis have an increased risk of biologic treatment discontinuation compared with younger adult patients, particularly, if being treated with IL-23 inhibitors. However, in stratified analyses conducted in elderly patients, IL-23 inhibitors showed higher drug survival rates than IL-17 inhibitors.
Sections du résumé
BACKGROUND
BACKGROUND
Scarce data related to the drug survival of biologic agents in psoriasis patients aged ≥65 years is available.
OBJECTIVES
OBJECTIVE
To evaluate the drug survival of interleukin (IL)-23 or the IL-17 inhibitors approved for the treatment of moderate-to-severe psoriasis in elderly patients (aged ≥65 years), compared with younger adult patients (aged <65 years), and to identify clinical predictors that can influence the drug survival.
METHODS
METHODS
This retrospective multicentric cohort study included adult patients with moderate-to-severe psoriasis, dissecting two-patient subcohorts based on age: elderly versus younger adults. Kaplan-Meier estimator and proportional hazard Cox regression models were used for drug survival analysis.
RESULTS
RESULTS
We included 4178 patients and 4866 treatment courses; 934 were elderly (1072 treatment courses), and 3244 were younger patients (3794 treatment courses). Drug survival, considering all causes of interruption, was higher in patients aged <65 years than in elderly patients overall (log-rank p < 0.006). This difference was significant for treatment courses involving IL-23 inhibitors (p < 0.001) but not for those with IL-17 inhibitors (p = 0.2). According to both uni- and multi-variable models, elder age was associated with an increased risk of treatment discontinuation (univariable analysis: HR: 1.229, 95% CI 1.062-1.422; p < 0.006; multivariable analysis: HR: 1.199, 95% CI 1.010-1.422; p = 0.0377). Anti-IL-23 agents were associated with a reduced likelihood of treatment discontinuation after adjusting for other variables (HR: 0.520, 95% CI 0.368-0.735; p < 0.001). Being previously treated with IL-17 inhibitors increased the probability of discontinuation.
CONCLUSION
CONCLUSIONS
Elderly patients with psoriasis have an increased risk of biologic treatment discontinuation compared with younger adult patients, particularly, if being treated with IL-23 inhibitors. However, in stratified analyses conducted in elderly patients, IL-23 inhibitors showed higher drug survival rates than IL-17 inhibitors.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 European Academy of Dermatology and Venereology.
Références
Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945–1960.
Dapavo P, Siliquini N, Mastorino L, Avallone G, Merli M, Agostini A, et al. Efficacy, safety, and drug survival of IL‐23, IL‐17, and TNF‐alpha inhibitors for psori‐ asis treatment: a retrospective study. J Dermatol Treat. 2021;13:1–6.
Kamata M, Tada Y. Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review. Int J Mol Sci. 2020;21(5):1690. https://doi.org/10.3390/ijms21051690
Mourad AI, Gniadecki R. Biologic drug survival in psoriasis: a systematic review & comparative meta‐analysis. Front Med. 2021;7:625755.
Gooderham MJ, Lynde C, Turchin I, Avadisian M, Labelle M, Papp KA. Real‐world, long‐term treatment patterns of commonly used biologics in Canadian patients with moderate‐to‐severe chronic plaque psoriasis. J Dermatol. 2022;49(1):95–105.
Iznardo H, Vilarrasa E, López‐Ferrer A, Puig L. Real‐world drug survival of guselkumab, ixekizumab and secukinumab for psoriasis. Br J Dermatol. 2021;185(3):660–662.
Sbidian E, Chaimani A, Garcia‐Doval I, Garcia‐Doval I, Hua C, Hughes C, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis. Cochrane Database Syst Rev. 2017;12(12):CD011535. https://doi.org/10.1002/14651858.CD011535
Bai F, Li GG, Liu Q, Niu X, Li R, Ma H. Short‐term efficacy and safety of IL‐17, IL‐12/23, and IL‐23 inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, tildrakizumab, and Risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network meta‐analysis of randomized controlled trials. J Immunol Res. 2019;2019:2546161.
Mourad A, Straube S, Armijo‐Olivo S, Gniadecki R. Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta‐analysis. Br J Dermatol. 2019;181(3):450–458.
Torres T, Puig L, Vender R, Lynde C, Piaserico S, Carrascosa JM, et al. Drug survival of IL‐12/23, IL‐17 and IL‐23 inhibitors for psoriasis treatment: a retrospective multi‐country, multicentric cohort study. Am J Clin Dermatol. 2021;22(4):567–579.
Torres T, Puig L, Vender R, Yeung J, Carrascosa JM, Piaserico S, et al. Drug survival of interleukin (IL)‐17 and IL‐23 inhibitors for the treatment of psoriasis: a retrospective multi‐country, multicentric cohort study. Am J Clin Dermatol. 2022;23(6):891–904.
Ter Haar ELM, Thomas SE, van den Reek JMPA, Otero ME, Njoo MD, Ossenkoppele PM, et al. Drug survival, safety, and effectiveness of biologics in older patients with psoriasis: a comparison with younger patients‐a BioCAPTURE registry study. Drugs Aging. 2022;39(9):715–727.
Di Caprio R, Caiazzo G, Cacciapuoti S, Fabbrocini G, Scala E, Balato A. Safety concerns with current treatments for psoriasis in the elderly. Expert Opin Drug Saf. 2020;19(4):523–531.
Megna M, Camela E, Battista T, Genco L, Martora F, Noto M, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients. Expert Opin Drug Saf. 2023;22(1):43–58.
Grozdev IS, Van Voorhees AS, Gottlieb AB, Hsu S, Lebwohl MG, Bebo BF Jr, et al. Psoriasis in the elderly: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2011;65(3):537–545.
Gargiulo L, Ibba L, Malagoli P, Balato A, Bardazzi F, Burlando M, et al. Drug survival of IL‐12/23, IL‐17 and IL‐23 inhibitors for moderate‐to‐severe plaque psoriasis: a retrospective multicenter real‐world experience on 5932 treatment courses – IL PSO (Italian landscape psoriasis). Front Immunol. 2024;14:1341708. https://doi.org/10.3389/fimmu.2023.1341708
van Winden MEC, van der Schoot LS, van de L'Isle AM, van Vugt LJ, van den Reek JMPA, van de Kerkhof PCM, et al. Effectiveness and safety of systemic therapy for psoriasis in older adults: a systematic review. JAMA Dermatol. 2020;156(11):1229–1239.
Caruso C, Buffa S, Candore G, Colonna‐Romano G, Dunn‐Walters D, Kipling D, et al. Mechanisms of immunosenescence. Immun Ageing. 2009;22:6–10.
Di Lernia V, Goldust M. An overview of the efficacy and safety of systemic treatments for psoriasis in the elderly. Expert Opin Biol Ther. 2018;18(8):897–903.
Phan C, Beneton N, Delaunay J, Reguiai Z, Boulard C, Fougerousse AC, et al. Effectiveness and safety of anti‐interleukin‐17 therapies in elderly patients with psoriasis. Acta Derm Venereol. 2020;100(18):adv00316.
Talamonti M, Russo F, Malara G, Hansel K, Papini M, Cattaneo A, et al. Efficacy and safety of Secukinumab in elderly patients with moderate to severe plaque‐type psoriasis: post‐hoc analysis of the SUPREME study. Clin Cosmet Investig Dermatol. 2023;16:847–852.
Balato N, Patruno C, Napolitano M, Patrì A, Ayala F, Scarpa R. Managing moderate‐to‐severe psoriasis in the elderly. Drugs Aging. 2014;31:233–238.
Lavan AH, Gallagher P. Predicting risk of adverse drug reactions in older adults. Ther Adv Drug Saf. 2016;7(1):11–22.
Körber A, Papavassilis C, Bhosekar V, Reinhardt M. Efficacy and safety of Secukinumab in elderly subjects with moderate to severe plaque psoriasis: a pooled analysis of phase III studies. Drugs Aging. 2018;35(2):135–144.
Chiricozzi A, Pavlidis A, Dattola A, Bianchi L, Chimenti MS, Fida M, et al. Efficacy and safety of infliximab in psoriatic patients over the age of 65. Expert Opin Drug Saf. 2016;15(11):1459–1462.
Garber C, Plotnikova N, Au SC, Sorensen EP, Gottlieb A. Biologic and conventional systemic therapies show similar safety and efficacy in elderly and adult patients with moderate to severe psoriasis. J Drugs Dermatol. 2015;14(8):846–852.
Ricceri F, Bardazzi F, Chiricozzi A, Dapavo P, Ferrara F, Mugheddu C, et al. Elderly psoriatic patients under biological therapies: an Italian experience. J Eur Acad Dermatol Venereol. 2019;33(1):143–146.
Armstrong AW, Patel M, Li C, Garg V, Mandava MR, Wu JJ. Real‐world switching patterns and associated characteristics in patients with psoriasis treated with biologics in the United States. J Dermatolog Treat. 2023;34(1):2200870.
Doshi JA, Takeshita J, Pinto L, Li P, Yu X, Rao P, et al. Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population. J Am Acad Dermatol. 2016;74(6):1057–1065.e4.
Graier T, Salmhofer W, Jonak C, Weger W, Kölli C, Gruber B, et al. Biologic drug survival rates in the era of anti‐interleukin‐17 antibodies: a time‐period‐adjusted registry analysis. Br J Dermatol. 2021;184(6):1094–1105.
Torres T, Chiricozzi A, Puig L. Authors' reply to Borg and Thoning: “comment on: drug survival of IL‐12/23, IL‐17 and IL‐23 inhibitors for psoriasis treatment: a retrospective multi‐country, multicentric cohort study”. Am J Clin Dermatol. 2021;22(6):903–904.